X

Clinical Trials

Contact Us

Rare Tumor

A031702

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors


S1609 (NCT02834013)

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors


MATCH: EAY131 (NCT02465050)

MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma.